Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Metabolic Health Research, Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
Department of Metabolic Health Research, Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.
Eur J Pharm Sci. 2024 Oct 1;201:106868. doi: 10.1016/j.ejps.2024.106868. Epub 2024 Jul 29.
Drug metabolism in the intestinal wall affects bioavailability of orally administered drugs and is influenced by age. Hence, it is important to fully understand the drug metabolizing capacity of the gut to predict systemic exposure. The aim of this study was to investigate the potential of enteroids as a tool to study CYP3A4/5 -mediated metabolism in both children and adults. Bioconversion of midazolam, a CYP3A4/5 model substrate, was studied using enteroid monolayers as well as tissue explants in the Ussing chamber, both derived from pediatric [median (range age): 54 weeks (2 days - 13 years), n = 21] and adult (n = 5) tissue. Caco-2 cellular monolayers were employed as controls. In addition, mRNA expression of CYP3A4 was determined in enteroid monolayers (n = 11), tissue (n = 23) and Caco-2 using RT-qPCR. Midazolam metabolism was successfully detected in all enteroid monolayers, as well as in all tissue explants studied in the Ussing chamber, whereas Caco-2 showed no significant metabolite formation. The extracted fraction of midazolam was similar between enteroid monolayers and tissue. The fraction of midazolam extracted increased with age in enteroid monolayers derived from 0 to 70 week old donors. No statistically significant correlation was observed in tissue likely due to high variability observed and the smaller donor numbers included in the study. At the level of gene expression, CYP3A4 increased with age in tissues (n = 32), while this was not reflected in enteroid monolayers (n = 16). Notably, asymmetric metabolite formation was observed in enteroids and tissue, with higher metabolite formation on the luminal side of the barrier. In summary, we demonstrated that enteroids can be used to measure CYP3A4/5 midazolam metabolism, which we show is similar as observed in fresh isolated tissue. This was the case both in children and adults, indicating the potential of enteroids to predict intestinal metabolism. This study provides promising data to further develop enteroids to study drug metabolism in vitro and potentially predict oral absorption for special populations as an alternative to using fresh tissue.
肠壁中的药物代谢会影响口服药物的生物利用度,并受年龄的影响。因此,充分了解肠道的药物代谢能力以预测全身暴露量非常重要。本研究旨在探讨类器官作为研究儿童和成人 CYP3A4/5 介导代谢的工具的潜力。使用类器官单层和 Ussing 室中的组织外植体研究咪达唑仑(CYP3A4/5 模型底物)的生物转化,这些组织分别来源于儿科(中位数(范围年龄):54 周(2 天-13 岁),n=21)和成人(n=5)组织。Caco-2 细胞单层作为对照。此外,还使用 RT-qPCR 测定了类器官单层(n=11)、组织(n=23)和 Caco-2 中 CYP3A4 的 mRNA 表达。成功地在所有类器官单层以及在 Ussing 室中研究的所有组织外植体中检测到咪达唑仑的代谢,而 Caco-2 则没有明显的代谢产物形成。在类器官单层和组织中,咪达唑仑的提取分数相似。从 0 周到 70 周龄供体来源的类器官单层中,咪达唑仑的提取分数随年龄增加而增加。在组织中,由于观察到的高度变异性和纳入研究的供体数量较少,未观察到统计学上的显著相关性。在基因表达水平上,CYP3A4 在组织中随年龄增加(n=32),而在类器官单层中则没有反映(n=16)。值得注意的是,在类器官和组织中观察到不对称的代谢产物形成,在屏障的腔侧形成更高的代谢产物。总之,我们证明了类器官可用于测量 CYP3A4/5 咪达唑仑代谢,我们发现其与新鲜分离组织中观察到的代谢相似。这在儿童和成人中都是如此,表明类器官具有预测肠道代谢的潜力。这项研究提供了有希望的数据,可进一步开发类器官以在体外研究药物代谢,并可能替代使用新鲜组织来预测特殊人群的口服吸收。